NorgineとArc Medicalが内視鏡機器ENDOCUFF VISIONの商業化で提携

AsiaNet 59794 （0361）

【ロンドン2015年3月12日PRN＝共同通信JBN】NorgineとArc Medical Design Ltdは12日、結腸内視鏡で使われるクラス1の無菌医療機器ENDOCUFF VISION（TM）を欧州の一連の主要市場とオーストラリア、ニュージーランドでNorgineが商業化、販売する提携関係を結んだと発表した。Norgineの初のENDOCUFF VISION発売は英国で2015年第2四半期になる。

（Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ）

ENDOCUFF VISIONはシングルユースの無菌内視鏡オーバーチューブで、ほとんどの内視鏡の先端部に適合しており、引き抜く際の先端部制御を改善し、結腸直腸がんを含む結腸疾患患者の粘膜画像を強化するように設計されている。病変部の画像化改善は腺腫発見率（ADR）と患者当たり平均腺腫率（MAP）の増加という結果で示されている。[1]、[2]、[3]､[4]

結腸直腸がんは世界のがん関連死で2番目に多い死因[5]で、2012年には世界で140万人近くが新たに結腸直腸がんと診断され、欧州では毎年41万2000人が結腸直腸がんと診断されている。[6]､[7]

Norgineのピーター・スタイン最高経営責任者は「Arc Medicalとの新たな提携に興奮しており、病変発見の大幅増加につながるだけでなく質の高い結腸内視鏡を保証して処置を繰り返す必要をなくす－それによって患者の体験を大きく改善する－機器であるENDOCUFF VISIONの販売促進に興奮している。この提携は結腸内視鏡の質の改善に対するNorgineのコミットを示す新たな好例であり、既存の結腸浄化ポートフォリオへの追加である」とコメントしている。

（注）

1. Biecker E, et al. Novel Endocuff-assisted colonoscopy significantly

increases the polyp detection rate. A randomized controlled trial. J Clin

Gastroenterol. 2014;00:000-000

2. Floer M, et al. Higher adenoma detection rate with Endocuff assisted

colonoscopy. Plos One. 3 December 2014; 10.1371

3. Lenze F, et al. Endocuff-assisted colonoscopy: a new accessory to improve adenoma detection rate? Technical aspects and first clinical experiences. Endoscopy. 2014; 46(7):610-614

4. Marsano J, et al. Endocuff assisted colonoscopy increases adenoma detection rate: A multicentre study. ASGE Posters, 10095, DDW, Chicago 2014

5. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al.  Cancer incidence and mortality patterns in Europe:  Estimates for 40 countries in 2012.

Eur J Cancer 2013;49:1374-14037. Zavoral M et al. Colorectal cancer screening in

Europe. World J Gastroenterol 2009;15(47):5907-5915

6. Colorectal Cancer Statistics, World Cancer Research Fund International,

http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/colorectal-cancer-statistics

（2015年3月4日にアクセス）

7. Zavoral M et al. Colorectal cancer screening in Europe. World J

Gastroenterol 2009;15(47):5907-5915

リリースを見るにはhttp://www.norgine.com へ。

Charlotte Andrews +44(0)7714-061-485

Isabelle Jouin : Mob: +44(0)7714-406372

ソース：Norgine B.V.

Norgine and Arc Medical Announce Partnership for Endoscopic Device, ENDOCUFF VISION(TM)

PR59794

LONDON, Mar. 12 /PRN=KYODO JBN/ -

Norgine and Arc Medical Design Ltd. today announced a partnership that will see

Norgine commercialising and distributing ENDOCUFF VISION(TM), a Class 1 sterile

medical device used in colonoscopy, across a number of major European markets,

Australia and New Zealand. Norgine's first launch of ENDOCUFF VISION(TM) will

take place in the UK Q2 2015.

     (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a )

ENDOCUFF VISION(TM) is a single use, sterile endoscopic overtube, which fits

onto the distal end of most endoscopes, and has been designed to improve tip

control during extubation and enhance mucosal vision in patients with diseases

of the colon, including colorectal cancer. The improved visualisation of

lesions has been shown to result in an increase in both the Adenoma Detection

Rate (ADR) and Mean Adenomas per Patient (MAP) rate.[1],[2],[3],[4]

Colorectal cancer is the second most common cause of cancer-related mortality

in the world[5]; nearly 1.4 million new cases of colorectal cancer were

diagnosed worldwide in 2012 and 412,000 people are diagnosed with it every year

in Europe.[6],[7]

Peter Stein, Chief Executive Officer Norgine, commented, "We are excited about

our new partnership with Arc Medical and the promotion of ENDOCUFF VISION(TM),

a device which not only leads to a significant increase in lesion detection,

but also ensures a quality colonoscopy and avoids the need for repeat

procedures - thus significantly improving the patient experience. This

partnership is a further example of Norgine's commitment to improving quality

in colonoscopy and adds to our existing bowel cleansing portfolio."

References

1. Biecker E, et al. Novel Endocuff-assisted colonoscopy significantly

increases the polyp detection rate. A randomized controlled trial. J Clin

Gastroenterol. 2014;00:000-000

2. Floer M, et al. Higher adenoma detection rate with Endocuff assisted

colonoscopy. Plos One. 3 December 2014; 10.1371

3. Lenze F, et al. Endocuff-assisted colonoscopy: a new accessory to improve

adenoma detection rate? Technical aspects and first clinical experiences.

Endoscopy. 2014; 46(7):610-614

4. Marsano J, et al. Endocuff assisted colonoscopy increases adenoma detection

rate: A multicentre study. ASGE Posters, 10095, DDW, Chicago 2014

5. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al.  Cancer incidence

and mortality patterns in Europe:  Estimates for 40 countries in 2012. Eur J

Cancer 2013;49:1374-14037. Zavoral M et al. Colorectal cancer screening in

Europe. World J Gastroenterol 2009;15(47):5907-5915

6. Colorectal Cancer Statistics, World Cancer Research Fund International,

http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/colorectal-cancer-statistics

[Accessed 4 March 2015]

7. Zavoral M et al. Colorectal cancer screening in Europe. World J

Gastroenterol 2009;15(47):5907-5915

See release on http://www.norgine.com

Charlotte Andrews +44(0)7714-061-485

Isabelle Jouin : Mob: +44(0)7714-406372

SOURCE: Norgine B.V.